25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

AQST (Aquestive) Stock Analysis
Buy, Hold or Sell?

Let's analyze Aquestive together

I guess you are interested in Aquestive Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • 📊 Fundamental Analysis (FA) – Aquestive’s Financial Insights
  • 📈 Technical Analysis (TA) – Aquestive’s Price Targets

I'm going to help you getting a better view of Aquestive Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Aquestive Therapeutics Inc

I send you an email if I find something interesting about Aquestive Therapeutics Inc.

1. Quick Overview

1.1. Quick analysis of Aquestive (30 sec.)










1.2. What can you expect buying and holding a share of Aquestive? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
8.8%

What is your share worth?

Current worth
$-0.61
Expected worth in 1 year
$-0.86
How sure are you?
23.5%

+ What do you gain per year?

Total Gains per Share
$-0.25
Return On Investment
-7.3%

For what price can you sell your share?

Current Price per Share
$3.40
Expected price per share
$2.2 - $3.815
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Aquestive (5 min.)




Live pricePrice per Share (EOD)
$3.40
Intrinsic Value Per Share
$-5.83 - $-6.92
Total Value Per Share
$-6.44 - $-7.54

2.2. Growth of Aquestive (5 min.)




Is Aquestive growing?

Current yearPrevious yearGrowGrow %
How rich?-$60.9m-$88m$37.5m74.5%

How much money is Aquestive making?

Current yearPrevious yearGrowGrow %
Making money-$13.5m-$7.1m-$6.3m-47.0%
Net Profit Margin-126.3%-56.8%--

How much money comes from the company's main activities?

2.3. Financial Health of Aquestive (5 min.)




3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Aquestive?

Welcome investor! Aquestive's management wants to use your money to grow the business. In return you get a share of Aquestive.

First you should know what it really means to hold a share of Aquestive. And how you can make/lose money.

Speculation

The Price per Share of Aquestive is $3.4. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Aquestive.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Aquestive, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $-0.61. Based on the TTM, the Book Value Change Per Share is $-0.06 per quarter. Based on the YOY, the Book Value Change Per Share is $0.18 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Aquestive.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.23-6.8%-0.14-4.0%-0.07-2.1%-0.10-2.9%-0.12-3.5%-0.12-3.6%
Usd Book Value Change Per Share-0.01-0.2%-0.06-1.8%0.185.4%0.030.8%-0.02-0.6%-0.02-0.7%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.01-0.2%-0.06-1.8%0.185.4%0.030.8%-0.02-0.6%-0.02-0.7%
Usd Price Per Share2.90-3.51-2.37-2.28-3.12-3.19-
Price to Earnings Ratio-3.14--10.65--10.04--7.03--9.12--7.59-
Price-to-Total Gains Ratio-372.16--32.93-13.46--8.67--75.38--59.93-
Price to Book Ratio-4.73--7.19--4.14--4.07--6.38--6.93-
Price-to-Total Gains Ratio-372.16--32.93-13.46--8.67--75.38--59.93-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share3.4
Number of shares294
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.06-0.02
Usd Total Gains Per Share-0.06-0.02
Gains per Quarter (294 shares)-18.22-5.93
Gains per Year (294 shares)-72.90-23.73
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-73-830-24-34
20-146-1560-47-58
30-219-2290-71-82
40-292-3020-95-106
50-364-3750-119-130
60-437-4480-142-154
70-510-5210-166-178
80-583-5940-190-202
90-656-6670-214-226
100-729-7400-237-250

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%1.011.00.08.3%1.019.00.05.0%3.031.00.08.8%3.033.00.08.3%
Book Value Change Per Share1.03.00.025.0%5.07.00.041.7%5.015.00.025.0%8.023.03.023.5%9.024.03.025.0%
Dividend per Share0.00.04.00.0%3.00.09.025.0%3.00.017.015.0%3.00.031.08.8%3.00.033.08.3%
Total Gains per Share1.03.00.025.0%5.07.00.041.7%5.015.00.025.0%8.023.03.023.5%9.024.03.025.0%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Aquestive Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.008-0.062+696%0.184-104%0.027-129%-0.020+159%-0.023+199%
Book Value Per Share---0.613-0.508-17%-0.887+45%-0.827+35%-0.722+18%-0.489-20%
Current Ratio--4.8735.852-17%2.828+72%3.276+49%2.823+73%2.386+104%
Debt To Asset Ratio--1.5961.476+8%2.434-34%2.279-30%2.136-25%1.820-12%
Debt To Equity Ratio----0%-0%-0%-0%0.308-100%
Dividend Per Share----0%0.000-100%0.000-100%0.000-100%0.000-100%
Enterprise Value--193543921.600267330943.040-28%112579492.960+72%111305158.118+74%204723234.415-5%311899420.064-38%
Eps---0.231-0.137-41%-0.072-69%-0.097-58%-0.120-48%-0.122-47%
Ev To Ebitda Ratio---3.07041.174-107%-5.366+75%12.174-125%8.596-136%3.086-199%
Ev To Sales Ratio--5.5495.307+5%2.292+142%2.207+151%4.467+24%6.309-12%
Free Cash Flow Per Share---0.237-0.123-48%-0.067-72%-0.054-77%-0.073-69%-0.071-70%
Free Cash Flow To Equity Per Share---0.029-0.067+130%0.172-117%0.045-164%0.017-274%0.017-275%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0020%1.0010%
Intrinsic Value_10Y_max---6.924----------
Intrinsic Value_10Y_min---5.826----------
Intrinsic Value_1Y_max---0.286----------
Intrinsic Value_1Y_min---0.281----------
Intrinsic Value_3Y_max---1.170----------
Intrinsic Value_3Y_min---1.111----------
Intrinsic Value_5Y_max---2.429----------
Intrinsic Value_5Y_min---2.228----------
Market Cap337714873.600+15%288050921.600348640943.040-17%234910492.960+23%226400574.785+27%310135984.415-7%317139098.286-9%
Net Profit Margin---2.630-1.263-52%-0.568-78%-0.823-69%-1.102-58%-1.028-61%
Operating Margin---2.139-0.940-56%-0.363-83%-0.590-72%-0.788-63%-0.778-64%
Operating Ratio--3.2211.994+62%1.385+133%1.722+87%1.807+78%1.772+82%
Pb Ratio-5.543-17%-4.728-7.194+52%-4.138-12%-4.072-14%-6.378+35%-6.929+47%
Pe Ratio-3.682-17%-3.141-10.647+239%-10.044+220%-7.030+124%-9.116+190%-7.595+142%
Price Per Share3.400+15%2.9003.510-17%2.365+23%2.279+27%3.122-7%3.193-9%
Price To Free Cash Flow Ratio-3.587-17%-3.060-9.040+195%-10.044+228%-3.838+25%-8.463+177%-8.572+180%
Price To Total Gains Ratio-436.324-17%-372.159-32.934-91%13.457-2865%-8.669-98%-75.375-80%-59.927-84%
Quick Ratio--4.3235.296-18%2.433+78%2.885+50%2.467+75%2.055+110%
Return On Assets---0.224-0.130-42%-0.094-58%-0.125-44%-0.180-20%-0.196-12%
Return On Equity----0%-0%-0%-0%-0.0600%
Total Gains Per Share---0.008-0.062+696%0.184-104%0.027-129%-0.020+159%-0.023+199%
Usd Book Value---60930000.000-50496250.000-17%-88091500.000+45%-82193000.000+35%-71695450.000+18%-48561029.412-20%
Usd Book Value Change Per Share---0.008-0.062+696%0.184-104%0.027-129%-0.020+159%-0.023+199%
Usd Book Value Per Share---0.613-0.508-17%-0.887+45%-0.827+35%-0.722+18%-0.489-20%
Usd Dividend Per Share----0%0.000-100%0.000-100%0.000-100%0.000-100%
Usd Enterprise Value--193543921.600267330943.040-28%112579492.960+72%111305158.118+74%204723234.415-5%311899420.064-38%
Usd Eps---0.231-0.137-41%-0.072-69%-0.097-58%-0.120-48%-0.122-47%
Usd Free Cash Flow---23535000.000-12260000.000-48%-6650500.000-72%-5379583.333-77%-7262050.000-69%-7061529.412-70%
Usd Free Cash Flow Per Share---0.237-0.123-48%-0.067-72%-0.054-77%-0.073-69%-0.071-70%
Usd Free Cash Flow To Equity Per Share---0.029-0.067+130%0.172-117%0.045-164%0.017-274%0.017-275%
Usd Market Cap337714873.600+15%288050921.600348640943.040-17%234910492.960+23%226400574.785+27%310135984.415-7%317139098.286-9%
Usd Price Per Share3.400+15%2.9003.510-17%2.365+23%2.279+27%3.122-7%3.193-9%
Usd Profit---22930000.000-13559750.000-41%-7191500.000-69%-9518833.333-58%-12036000.000-48%-11934088.235-48%
Usd Revenue--8720000.00013557000.000-36%12875500.000-32%12689500.000-31%12623000.000-31%14704941.176-41%
Usd Total Gains Per Share---0.008-0.062+696%0.184-104%0.027-129%-0.020+159%-0.023+199%
 EOD+6 -2MRQTTM+8 -27YOY+14 -233Y+13 -245Y+12 -2610Y+9 -30

3.3 Fundamental Score

Let's check the fundamental score of Aquestive Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-3.682
Price to Book Ratio (EOD)Between0-1-5.543
Net Profit Margin (MRQ)Greater than0-2.630
Operating Margin (MRQ)Greater than0-2.139
Quick Ratio (MRQ)Greater than14.323
Current Ratio (MRQ)Greater than14.873
Debt to Asset Ratio (MRQ)Less than11.596
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-0.224
Total3/10 (30.0%)

3.4 Technical Score

Let's check the technical score of Aquestive Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose3.310
Total0/1 (0.0%)

4. In-depth Analysis

4.1 About Aquestive Therapeutics Inc

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; KYNMOBI a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's proprietary pipeline products include Anaphylm, an epinephrine sublingual film, which is in phase 3 clinical trial for the emergency treatment of allergic reactions, including anaphylaxis; and AQST-108, a topical gel that is in phase 2 clinical trial for the treatment of alopecia areata. In addition, it develops PharmFilm technology for patients suffering from certain central nervous system disorders; and Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.

Fundamental data was last updated by Penke on 2025-06-18 23:35:06.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is unable to pay all its debts by selling its assets.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Aquestive earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Aquestive to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of -263.0% means that $-2.63 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Aquestive Therapeutics Inc:

  • The MRQ is -263.0%. The company is making a huge loss. -2
  • The TTM is -126.3%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-263.0%TTM-126.3%-136.6%
TTM-126.3%YOY-56.8%-69.5%
TTM-126.3%5Y-110.2%-16.2%
5Y-110.2%10Y-102.8%-7.4%
4.3.1.2. Return on Assets

Shows how efficient Aquestive is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Aquestive to the Drug Manufacturers - Specialty & Generic industry mean.
  • -22.4% Return on Assets means that Aquestive generated $-0.22 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Aquestive Therapeutics Inc:

  • The MRQ is -22.4%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -13.0%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-22.4%TTM-13.0%-9.4%
TTM-13.0%YOY-9.4%-3.6%
TTM-13.0%5Y-18.0%+5.0%
5Y-18.0%10Y-19.6%+1.7%
4.3.1.3. Return on Equity

Shows how efficient Aquestive is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Aquestive to the Drug Manufacturers - Specialty & Generic industry mean.
  • 0.0% Return on Equity means Aquestive generated $0.00 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Aquestive Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-6.0%+6.0%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Aquestive Therapeutics Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Aquestive is operating .

  • Measures how much profit Aquestive makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Aquestive to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of -213.9% means the company generated $-2.14  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Aquestive Therapeutics Inc:

  • The MRQ is -213.9%. The company is operating very inefficient. -2
  • The TTM is -94.0%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-213.9%TTM-94.0%-119.9%
TTM-94.0%YOY-36.3%-57.7%
TTM-94.0%5Y-78.8%-15.1%
5Y-78.8%10Y-77.8%-1.1%
4.3.2.2. Operating Ratio

Measures how efficient Aquestive is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 3.22 means that the operating costs are $3.22 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Aquestive Therapeutics Inc:

  • The MRQ is 3.221. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.994. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ3.221TTM1.994+1.227
TTM1.994YOY1.385+0.609
TTM1.9945Y1.807+0.187
5Y1.80710Y1.772+0.035
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Aquestive Therapeutics Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Aquestive is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 4.87 means the company has $4.87 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Aquestive Therapeutics Inc:

  • The MRQ is 4.873. The company is very able to pay all its short-term debts. +2
  • The TTM is 5.852. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ4.873TTM5.852-0.979
TTM5.852YOY2.828+3.025
TTM5.8525Y2.823+3.029
5Y2.82310Y2.386+0.436
4.4.3.2. Quick Ratio

Measures if Aquestive is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Aquestive to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 4.32 means the company can pay off $4.32 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Aquestive Therapeutics Inc:

  • The MRQ is 4.323. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 5.296. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ4.323TTM5.296-0.973
TTM5.296YOY2.433+2.863
TTM5.2965Y2.467+2.829
5Y2.46710Y2.055+0.412
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Aquestive Therapeutics Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Aquestive assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Aquestive to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 1.60 means that Aquestive assets are financed with 159.6% credit (debt) and the remaining percentage (100% - 159.6%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Aquestive Therapeutics Inc:

  • The MRQ is 1.596. The company is unable to pay all its debts by selling its assets. -2
  • The TTM is 1.476. The company is unable to pay all its debts by selling its assets. -2
Trends
Current periodCompared to+/- 
MRQ1.596TTM1.476+0.120
TTM1.476YOY2.434-0.958
TTM1.4765Y2.136-0.660
5Y2.13610Y1.820+0.315
4.5.4.2. Debt to Equity Ratio

Measures if Aquestive is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Aquestive to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Aquestive Therapeutics Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y0.308-0.308
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Aquestive generates.

  • Above 15 is considered overpriced but always compare Aquestive to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of -3.14 means the investor is paying $-3.14 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Aquestive Therapeutics Inc:

  • The EOD is -3.682. Based on the earnings, the company is expensive. -2
  • The MRQ is -3.141. Based on the earnings, the company is expensive. -2
  • The TTM is -10.647. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-3.682MRQ-3.141-0.541
MRQ-3.141TTM-10.647+7.507
TTM-10.647YOY-10.044-0.604
TTM-10.6475Y-9.116-1.531
5Y-9.11610Y-7.595-1.522
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Aquestive Therapeutics Inc:

  • The EOD is -3.587. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -3.060. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -9.040. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-3.587MRQ-3.060-0.528
MRQ-3.060TTM-9.040+5.980
TTM-9.040YOY-10.044+1.004
TTM-9.0405Y-8.463-0.577
5Y-8.46310Y-8.572+0.109
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Aquestive is to cheap or to expensive compared to its book value.

Let's take a look of the Price to Book Ratio trends of Aquestive Therapeutics Inc:

  • The EOD is -5.543. Based on the equity, the company is expensive. -2
  • The MRQ is -4.728. Based on the equity, the company is expensive. -2
  • The TTM is -7.194. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-5.543MRQ-4.728-0.815
MRQ-4.728TTM-7.194+2.466
TTM-7.194YOY-4.138-3.055
TTM-7.1945Y-6.378-0.816
5Y-6.37810Y-6.929+0.551
4.6.2. Total Gains per Share

2.4. Latest News of Aquestive Therapeutics Inc

Does Aquestive Therapeutics Inc still have the same value as the quarterly reports suggest? Recent changes may be an indication that the value of the company is changing. Read the news from Aquestive Therapeutics Inc to keep up to date. Note: the news is often already included in the price.

DateTitleRead
2025-06-16
14:23
Aquestive gains as allergy therapy undergoes FDA reviewRead

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Aquestive Therapeutics Inc.

4.8.1. Institutions holding Aquestive Therapeutics Inc

Institutions are holding 48.758% of the shares of Aquestive Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-03-31Bratton Capital Management, L.P.9.8773100981095800
2025-03-31BlackRock Inc5.97590.00045935754-62844-1.0476
2025-03-31Vanguard Group Inc4.10110.00024073558-273196-6.2851
2025-03-31Perceptive Advisors LLC3.75240.3808372720837272080
2025-03-31Geode Capital Management, LLC1.71220.00041700706461102.7868
2025-03-31Morgan Stanley - Brokerage Accounts1.53760.00031527289790400107.2617
2025-03-31State Street Corp1.5330.00021522655187641.2477
2025-03-31Pale Fire Capital SE1.34470.46031335684809928154.0502
2025-03-31Bank of America Corp1.33950.0003133052564024192.7504
2025-03-31Janney Montgomery Scott LLC1.06690.00871059760752757.6461
2025-03-31Blue Owl Capital Holdings LP0.92620.8604920000200002.2222
2025-03-31Goldman Sachs Group Inc0.82440.0004818849-57688-6.5814
2025-03-31Northern Trust Corp0.59180.0003587828-11984-1.998
2025-03-31Two Sigma Advisers, LLC0.58030.00385764005604003502.5
2025-03-31Harvey Capital Management Inc0.5030.379149957023218086.832
2025-03-31Citadel Advisors Llc0.46270.00034595507787220.4025
2025-03-31Bracebridge Capital, LLC0.46230.090145921600
2024-12-31UBS Group AG0.42340.0003420563329874363.742
2025-03-31Woodline Partners LP0.41040.0077407661-1653-0.4038
2024-12-31Stifel Financial Corp0.40130.0015398561302617315.41
Total 37.8264102.195537572295+7223504+19.2%

4.9.2. Funds holding Aquestive Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-04-30Vanguard Total Stock Mkt Idx Inv2.42040.0004240417000
2025-05-31iShares Russell 2000 ETF1.94930.0085193617300
2025-04-30Vanguard Institutional Extnd Mkt Idx Tr1.1140.0032110655300
2025-03-31Fidelity Small Cap Index0.74840.008974335400
2025-05-31iShares Russell 2000 Value ETF0.48750.012248424500
2025-05-31State St Russell Sm/Mid Cp® Indx SL Cl I0.41570.002741288400
2025-04-30Fidelity Extended Market Index0.38890.0031386248-3692-0.9468
2025-04-30Vanguard Russell 2000 ETF0.37010.0091367634205125.9092
2025-05-31State St Russell Sm Cap® Indx SL Cl I0.25270.007925100000
2025-03-31NT R2000 Index Fund - NL0.18620.0092184991136647.9754
2025-04-30Schwab Small Cap Index0.1840.009218280200
2025-05-31iShares Russell 2000 Growth ETF0.17940.004417820500
2025-03-31Bridgeway Ultra-Small Company Market0.16110.47371600001600000
2025-05-31iShares Micro-Cap ETF0.15320.053215216900
2025-05-31iShares Core S&P Total US Stock Mkt ETF0.15130.000615030500
2025-03-31NT R2000 Index Fund - DC - NL - 30.14880.009214778380125.7322
2025-04-30Arctic Aurora LifeScience I0.14540.4898144457-71728-33.179
2025-03-31Extended Equity Market Fund K0.1450.00321439974410.3072
2025-04-30SPDR® Russell 2000 US Small Cap ETF0.13630.0111135379-13178-8.8707
2025-04-30Fidelity Total Market Index0.13630.000413536200
Total 9.8741.129807711+114031+1.2%

5.3. Insider Transactions

Insiders are holding 5.564% of the shares of Aquestive Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-11-26Cassie JungSELL444.87
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2024-03-312024-06-302024-09-302024-12-312025-03-31
Other Current Liabilities  5,1141,1786,292-7405,5527126,264-14,141-7,877



5.2. Latest Balance Sheet

Balance Sheet of 2025-03-31. Currency in USD. All numbers in thousands.

Summary
Total Assets102,234
Total Liabilities163,164
Total Stockholder Equity-60,930
 As reported
Total Liabilities 163,164
Total Stockholder Equity+ -60,930
Total Assets = 102,234

Assets

Total Assets102,234
Total Current Assets89,169
Long-term Assets13,065
Total Current Assets
Cash And Cash Equivalents 68,657
Net Receivables 10,444
Inventory 7,198
Other Current Assets 2,870
Total Current Assets  (as reported)89,169
Total Current Assets  (calculated)89,169
+/-0
Long-term Assets
Property Plant Equipment 8,850
Long-term Assets Other 4,215
Long-term Assets  (as reported)13,065
Long-term Assets  (calculated)13,065
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities18,298
Long-term Liabilities144,866
Total Stockholder Equity-60,930
Total Current Liabilities
Short-term Debt 567
Short Long Term Debt 27
Accounts payable 12,280
Other Current Liabilities -7,877
Total Current Liabilities  (as reported)18,298
Total Current Liabilities  (calculated)4,997
+/- 13,301
Long-term Liabilities
Long term Debt 33,746
Capital Lease Obligations 5,362
Long-term Liabilities Other 23,777
Long-term Liabilities  (as reported)144,866
Long-term Liabilities  (calculated)62,885
+/- 81,981
Total Stockholder Equity
Common Stock99
Retained Earnings -386,144
Other Stockholders Equity 325,115
Total Stockholder Equity (as reported)-60,930
Total Stockholder Equity (calculated)-60,930
+/-0
Other
Capital Stock99
Cash and Short Term Investments 68,657
Common Stock Shares Outstanding 95,497
Current Deferred Revenue1,048
Liabilities and Stockholders Equity 102,234
Net Debt -29,522
Net Invested Capital -27,157
Net Working Capital 70,871
Property Plant and Equipment Gross 52,484
Short Long Term Debt Total 39,135



5.3. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312007-06-302007-03-31
> Total Assets 
23,801
22,713
39,389
0
0
0
43,116
46,082
39,841
90,010
86,851
67,979
50,408
48,818
78,479
64,487
63,546
50,423
62,884
61,923
66,875
65,293
61,993
56,529
56,310
51,845
55,675
61,285
56,994
59,448
57,418
129,523
117,605
109,958
101,424
102,234
102,234101,424109,958117,605129,52357,41859,44856,99461,28555,67551,84556,31056,52961,99365,29366,87561,92362,88450,42363,54664,48778,47948,81850,40867,97986,85190,01039,84146,08243,11600039,38922,71323,801
   > Total Current Assets 
12,514
10,278
23,332
9,209
0
0
28,163
30,421
26,649
77,359
74,201
55,958
39,064
38,060
68,314
51,088
43,909
31,684
44,625
44,443
50,998
50,210
47,259
42,585
43,505
38,087
39,888
43,706
39,788
42,457
40,966
113,379
104,011
96,570
88,220
89,169
89,16988,22096,570104,011113,37940,96642,45739,78843,70639,88838,08743,50542,58547,25950,21050,99844,44344,62531,68443,90951,08868,31438,06039,06455,95874,20177,35926,64930,42128,163009,20923,33210,27812,514
       Cash And Cash Equivalents 
11,306
7,781
9,209
-9,209
0
0
17,379
16,488
10,638
63,982
60,599
39,934
22,165
20,914
49,326
35,521
25,422
17,064
31,807
27,498
34,234
31,164
28,024
14,736
17,695
18,649
27,273
26,882
22,436
24,917
23,872
95,200
89,870
77,893
71,546
68,657
68,65771,54677,89389,87095,20023,87224,91722,43626,88227,27318,64917,69514,73628,02431,16434,23427,49831,80717,06425,42235,52149,32620,91422,16539,93460,59963,98210,63816,48817,37900-9,2099,2097,78111,306
       Short-term Investments 
0
0
0
18,418
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000000018,418000
       Net Receivables 
207
1,428
10,817
0
0
0
6,179
9,441
6,629
7,450
6,481
7,489
10,150
10,316
13,130
9,536
12,891
7,990
6,955
10,209
12,127
13,643
12,120
19,896
19,165
10,737
4,704
7,551
10,101
8,550
8,471
8,324
5,998
9,684
7,344
10,444
10,4447,3449,6845,9988,3248,4718,55010,1017,5514,70410,73719,16519,89612,12013,64312,12710,2096,9557,99012,8919,53613,13010,31610,1507,4896,4817,4506,6299,4416,17900010,8171,428207
       Inventory 
865
800
2,886
0
0
0
4,014
3,850
4,348
4,483
5,441
5,137
4,647
4,124
2,859
3,087
3,173
3,242
2,461
2,799
2,839
2,863
4,038
4,629
5,008
6,725
5,780
6,981
5,950
7,079
6,769
7,734
6,966
7,021
6,044
7,198
7,1986,0447,0216,9667,7346,7697,0795,9506,9815,7806,7255,0084,6294,0382,8632,8392,7992,4613,2423,1733,0872,8594,1244,6475,1375,4414,4834,3483,8504,0140002,886800865
   > Long-term Assets 
0
0
0
-9,209
0
0
14,953
15,661
13,192
12,651
12,650
12,021
11,344
10,758
10,165
13,399
19,637
18,739
18,259
17,480
15,877
15,083
14,734
13,944
12,805
13,758
15,787
17,579
17,206
16,991
16,452
16,144
13,594
13,388
13,204
13,065
13,06513,20413,38813,59416,14416,45216,99117,20617,57915,78713,75812,80513,94414,73415,08315,87717,48018,25918,73919,63713,39910,16510,75811,34412,02112,65012,65113,19215,66114,95300-9,209000
       Property Plant Equipment 
9,579
9,796
15,122
0
0
0
13,460
12,764
12,766
12,211
12,207
11,594
10,933
10,351
9,726
12,971
12,221
11,337
10,321
9,556
8,893
8,114
7,780
7,020
6,883
6,378
7,901
9,698
10,380
10,220
9,736
9,488
9,356
9,158
8,981
8,850
8,8508,9819,1589,3569,4889,73610,22010,3809,6987,9016,3786,8837,0207,7808,1148,8939,55610,32111,33712,22112,9719,72610,35110,93311,59412,20712,21112,76612,76413,46000015,1229,7969,579
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
286
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000028600000000000000
       Long Term Investments 
0
0
0
0
0
0
6
6
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000066000000
       Intangible Assets 
1,605
1,546
305
0
0
0
254
241
229
216
204
191
178
165
153
140
127
115
102
89
76
64
51
38
25
1,487
1,435
1,396
1,357
1,317
1,278
1,239
0
0
0
0
00001,2391,2781,3171,3571,3961,4351,4872538516476891021151271401531651781912042162292412540003051,5461,605
       Long-term Assets Other 
0
0
0
-9,209
0
0
1,239
2,656
197
224
239
236
233
242
286
288
7,289
7,287
7,836
7,835
6,908
6,905
6,903
6,886
5,897
5,893
6,451
6,485
5,469
5,454
1,438
1,417
1,238
4,230
4,223
4,215
4,2154,2234,2301,2381,4171,4385,4545,4696,4856,4515,8935,8976,8866,9036,9056,9087,8357,8367,2877,2892882862422332362392241972,6561,23900-9,209000
> Total Liabilities 
2,524
4,867
56,965
0
0
0
69,611
68,902
78,789
66,566
76,771
74,035
75,065
83,277
84,601
85,316
84,934
86,942
111,381
113,721
120,644
125,638
144,127
149,672
152,667
159,664
174,229
170,520
163,645
162,375
163,905
165,824
153,084
155,378
161,580
163,164
163,164161,580155,378153,084165,824163,905162,375163,645170,520174,229159,664152,667149,672144,127125,638120,644113,721111,38186,94284,93485,31684,60183,27775,06574,03576,77166,56678,78968,90269,61100056,9654,8672,524
   > Total Current Liabilities 
2,524
4,103
10,806
0
0
0
15,350
23,472
23,474
21,329
32,952
29,638
24,629
20,053
18,555
15,362
14,882
18,373
21,104
20,050
23,035
25,039
21,964
24,184
29,636
36,560
39,679
40,383
38,653
24,057
18,308
18,058
13,895
15,152
18,865
18,298
18,29818,86515,15213,89518,05818,30824,05738,65340,38339,67936,56029,63624,18421,96425,03923,03520,05021,10418,37314,88215,36218,55520,05324,62929,63832,95221,32923,47423,47215,35000010,8064,1032,524
       Short-term Debt 
0
0
38,650
38,650
0
0
340
1,650
1,100
2,750
4,600
6,850
550
295
300
1,218
1,378
3,078
3,303
4,650
5,973
8,585
2,924
7,489
10,663
15,071
18,955
17,523
18,709
4,973
412
437
479
507
1,046
567
5671,0465074794374124,97318,70917,52318,95515,07110,6637,4892,9248,5855,9734,6503,3033,0781,3781,2183002955506,8504,6002,7501,1001,6503400038,65038,65000
       Short Long Term Debt 
0
0
38,650
38,650
0
0
45,507
1,650
1,100
2,750
4,600
6,850
550
0
0
0
0
1,750
2,575
3,863
5,150
7,725
2,025
6,563
9,750
14,225
18,700
17,195
18,362
4,606
22
23
24
25
26
27
2726252423224,60618,36217,19518,70014,2259,7506,5632,0257,7255,1503,8632,5751,75000005506,8504,6002,7501,1001,65045,5070038,65038,65000
       Accounts payable 
1,815
2,364
6,638
0
0
0
9,601
10,989
16,522
12,337
20,436
19,145
20,034
14,202
12,274
10,283
8,787
9,169
7,089
6,687
8,100
6,215
8,314
8,496
8,887
11,072
9,946
12,440
10,689
9,994
8,926
10,523
5,696
7,572
10,287
12,280
12,28010,2877,5725,69610,5238,9269,99410,68912,4409,94611,0728,8878,4968,3146,2158,1006,6877,0899,1698,78710,28312,27414,20220,03419,14520,43612,33716,52210,9899,6010006,6382,3641,815
       Other Current Liabilities 
90
867
4,168
0
0
0
4,062
9,236
2,614
3,422
4,292
2,587
3,269
4,721
5,175
2,828
3,914
5,404
9,703
8,276
8,320
9,472
9,612
6,131
8,220
9,292
8,792
5,242
4,964
6,076
7,082
5,114
6,292
5,552
6,264
-7,877
-7,8776,2645,5526,2925,1147,0826,0764,9645,2428,7929,2928,2206,1319,6129,4728,3208,2769,7035,4043,9142,8285,1754,7213,2692,5874,2923,4222,6149,2364,0620004,16886790
   > Long-term Liabilities 
0
0
0
0
0
0
54,261
45,430
55,315
45,237
43,819
44,397
50,436
63,224
66,046
69,954
70,052
68,569
90,277
93,671
97,609
100,599
122,163
125,488
123,031
123,104
134,550
130,137
124,992
138,318
145,597
147,766
139,189
140,226
142,715
144,866
144,866142,715140,226139,189147,766145,597138,318124,992130,137134,550123,104123,031125,488122,163100,59997,60993,67190,27768,56970,05269,95466,04663,22450,43644,39743,81945,23755,31545,43054,261000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
42,603
40,742
46,884
59,775
60,338
60,922
61,505
60,346
0
34,193
34,070
32,673
0
0
43,821
0
0
25,196
20,801
0
0
0
0
0
0
0
000000020,80125,1960043,8210032,67334,07034,193060,34661,50560,92260,33859,77546,88440,74242,6030000000000
       Other Liabilities 
0
764
7,509
0
0
0
8,754
8,091
9,985
1,183
1,216
3,655
3,552
3,449
5,708
5,608
5,307
5,176
53,102
56,843
61,124
65,741
68,666
76,098
77,708
83,089
97,563
99,235
98,581
0
0
0
0
0
0
0
000000098,58199,23597,56383,08977,70876,09868,66665,74161,12456,84353,1025,1765,3075,6085,7083,4493,5523,6551,2161,1839,9858,0918,7540007,5097640
       Deferred Long Term Liability 
0
1,092
0
0
0
0
1,050
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000001,05000001,0920
> Total Stockholder Equity
-17,493
-20,924
-95,967
-17,576
0
0
-26,495
-22,820
-38,948
23,444
10,080
-6,056
-24,657
-34,459
-6,122
-20,829
-21,388
-36,519
-48,497
-51,798
-53,769
-60,345
-82,134
-93,143
-96,357
-107,819
-118,554
-109,235
-106,651
-102,927
-106,487
-36,301
-35,479
-45,420
-60,156
-60,930
-60,930-60,156-45,420-35,479-36,301-106,487-102,927-106,651-109,235-118,554-107,819-96,357-93,143-82,134-60,345-53,769-51,798-48,497-36,519-21,388-20,829-6,122-34,459-24,657-6,05610,08023,444-38,948-22,820-26,49500-17,576-95,967-20,924-17,493
   Common Stock
11,088
11,243
11,243
0
0
0
12,727
20
20
25
25
25
25
25
34
34
34
34
35
36
39
40
41
41
53
54
55
56
62
67
69
90
91
91
91
99
999191919069676256555453414140393635343434342525252525202012,72700011,24311,24311,088
   Retained Earnings -386,144-363,214-346,159-334,650-331,905-319,077-310,966-308,931-303,139-311,207-298,855-286,318-270,017-256,796-227,851-213,296-200,929-186,257-165,889-149,338-147,004-130,474-117,838-99,426-78,954-61,376-47,432-32,394-23,201-120,093000-108,670-32,167-28,581
   Capital Surplus 
0
0
0
0
0
0
0
0
-6,574
70,851
71,431
72,873
74,744
83,354
124,318
126,141
127,916
129,336
137,725
149,095
159,488
167,466
174,621
0
189,908
0
0
193,848
202,218
0
0
0
0
0
0
0
0000000202,218193,84800189,9080174,621167,466159,488149,095137,725129,336127,916126,141124,31883,35474,74472,87371,43170,851-6,57400000000
   Treasury Stock000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
0
44,732
126,099
27,136
70,851
71,431
108,800
74,744
120,687
162,362
164,899
127,916
129,336
137,725
149,095
159,488
167,466
174,621
176,833
189,908
190,982
192,598
193,848
202,218
207,972
212,521
295,514
299,080
300,648
302,967
325,115
325,115302,967300,648299,080295,514212,521207,972202,218193,848192,598190,982189,908176,833174,621167,466159,488149,095137,725129,336127,916164,899162,362120,68774,744108,80071,43170,85127,136126,09944,732000000



5.4. Balance Sheets

Currency in USD. All numbers in thousands.




5.5. Cash Flows

Currency in USD. All numbers in thousands.




5.6. Income Statements

Currency in USD. All numbers in thousands.


5.7. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue57,561
Cost of Revenue-17,872
Gross Profit39,68939,689
 
Operating Income (+$)
Gross Profit39,689
Operating Expense-70,460
Operating Income-30,771-30,771
 
Operating Expense (+$)
Research Development20,280
Selling General Administrative50,180
Selling And Marketing Expenses0
Operating Expense70,46070,460
 
Net Interest Income (+$)
Interest Income3,437
Interest Expense-16,817
Other Finance Cost-0
Net Interest Income-13,380
 
Pretax Income (+$)
Operating Income-30,771
Net Interest Income-13,380
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-44,151-17,391
EBIT - interestExpense = -44,151
-44,151
-27,320
Interest Expense16,817
Earnings Before Interest and Taxes (EBIT)-27,334-27,334
Earnings Before Interest and Taxes (EBITDA)-26,616
 
After tax Income (+$)
Income Before Tax-44,151
Tax Provision--14
Net Income From Continuing Ops-44,137-44,137
Net Income-44,137
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses88,332
Total Other Income/Expenses Net-13,38013,380
 

Technical Analysis of Aquestive
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Aquestive. The general trend of Aquestive is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Aquestive's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Aquestive Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Aquestive Therapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 3.63 < 3.79 < 3.815.

The bearish price targets are: 3.049 > 2.222 > 2.2.

Know someone who trades $AQST? Share this with them.👇

Aquestive Therapeutics Inc Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Aquestive Therapeutics Inc. The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Aquestive Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Aquestive Therapeutics Inc.

Aquestive Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartAquestive Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Aquestive Therapeutics Inc. The current adx is .

Aquestive Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Aquestive Therapeutics Inc.

Aquestive Therapeutics Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Aquestive Therapeutics Inc.

Aquestive Therapeutics Inc Daily Relative Strength Index (RSI) ChartAquestive Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Aquestive Therapeutics Inc.

Aquestive Therapeutics Inc Daily Stochastic Oscillator ChartAquestive Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Aquestive Therapeutics Inc.

Aquestive Therapeutics Inc Daily Commodity Channel Index (CCI) ChartAquestive Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Aquestive Therapeutics Inc.

Aquestive Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartAquestive Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Aquestive Therapeutics Inc.

Aquestive Therapeutics Inc Daily Williams %R ChartAquestive Therapeutics Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Aquestive Therapeutics Inc.

Aquestive Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Aquestive Therapeutics Inc.

Aquestive Therapeutics Inc Daily Average True Range (ATR) ChartAquestive Therapeutics Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Aquestive Therapeutics Inc.

Aquestive Therapeutics Inc Daily On-Balance Volume (OBV) ChartAquestive Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Aquestive Therapeutics Inc.

Aquestive Therapeutics Inc Daily Money Flow Index (MFI) ChartAquestive Therapeutics Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Aquestive Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-02-07CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-02-11SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-02-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-14STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-18CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-02-19DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-02-20SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-02-21WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-25MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-02-28STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-03STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-04STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-06STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-03-07STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-03-10STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-11STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-12MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-13DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-14STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-19DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-20CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-03-24STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-28STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-31DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-04-01DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-04-02DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-04-03MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-04-04WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-07STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-04-08STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-09STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-10STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-14STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-16STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-17STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-21SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-04-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-04-23DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-04-24WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-04-28STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-30STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-01CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-05-02STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-06DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-09STOCH LONG EXITThe %K line crosses below the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-15STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-20STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-21CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-23STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-27CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-28MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-05-29WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-30STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-02STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-06-03CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-04STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-06-05STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-06STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-09MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-06-10STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-11RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-13STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-17STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-18SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-06-20MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-06-24CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-25CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-26STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Aquestive Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Aquestive Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose3.310
Total0/1 (0.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Aquestive with someone you think should read this too:
  • Are you bullish or bearish on Aquestive? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Aquestive? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Aquestive Therapeutics Inc

I send you an email if I find something interesting about Aquestive Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Aquestive Therapeutics Inc.

Receive notifications about Aquestive Therapeutics Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.